CTCBIO Inc.
Financials
Valuation Metrics
CTCBIO Inc.'s Market Cap is ₩739B. At end of 2025 it was ₩1118B. Ranked #1495 of 2,421 in KR market (top 62%), #869 of 1,640 on KOSDAQ (top 53%), #162 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 73.87B KRW | KR#1,495/2,421 Sec#162/231 |
| Revenue | 122.38B KRW | KR#1,301/2,421 Sec#81/231 |
| Net Income | 7.51B KRW | KR#1,064/2,421 Sec#67/231 |
| Total Assets | 143.24B KRW | KR#1,541/2,421 Sec#117/231 |
| Net Assets | 72.72B KRW | KR#1,648/2,421 Sec#136/231 |
| Employees | 257 | KR#910/2,421 Sec#76/231 |
| Value | ||
| P/E | 9.83x | KR#791/2,421 Sec#41/231 |
| P/B | 1.02x | KR#1,479/2,421 Sec#93/231 |
| P/S | 0.60x | KR#1,046/2,421 Sec#49/231 |
| EV/EBITDA | 8.10x | KR#484/2,421 Sec#20/231 |
| FCF Yield | 4.87% | KR#858/2,421 Sec#45/231 |
| Profitability | ||
| ROE | 10.33% | KR#587/2,421 Sec#40/231 |
| ROA | 5.25% | KR#707/2,421 Sec#59/231 |
| Op. Margin | 9.36% | KR#568/2,421 Sec#48/231 |
| Revenue Growth | -16.13% | KR#2,069/2,421 Sec#187/231 |
| Financial Health | ||
| Debt Ratio | 96.96% | KR#1,531/2,421 Sec#173/231 |
| Total Debt | 35.70B KRW | KR#1,142/2,421 Sec#83/231 |
| FCF | 3.60B KRW | KR#986/2,421 Sec#70/231 |
| Cash | 16.75B KRW | KR#1,366/2,421 Sec#108/231 |
| Current Ratio | 1.56x | KR#1,147/2,421 Sec#124/231 |
| Net Debt/EBITDA | 1.65x | KR#806/2,421 Sec#56/231 |
| Performance | ||
| 1Y Return | -57.33% | KR#2,169/2,421 Sec#203/231 |
| 1M Return | 2.17% | KR#1,010/2,421 Sec#74/231 |
| From 52W High | -60.22% | KR#1,869/2,421 Sec#144/231 |
| 1Y MDD | -63.76% | KR#1,682/2,421 Sec#140/231 |
| Trading | ||
| Volume | 27,505 shares | KR#1,430/2,421 Sec#140/231 |
| Trading Value | 83.7M KRW | KR#1,633/2,421 Sec#161/231 |
| Foreign Own. | 1.79% | KR#1,709/2,421 Sec#164/231 |
| Per Share | ||
| EPS | 311 KRW | KR#1,163/2,421 Sec#79/231 |
| BPS | 3,007 KRW | KR#1,861/2,421 Sec#141/231 |
Company Info
CTC BIO, established in 1995 and headquartered in Hwaseong-si, Gyeonggi-do, listed on KOSDAQ in 2002. The company researches, develops, manufactures, and distributes animal pharmaceuticals, including feed additives, injectables, and vaccines, as well as improved new drugs and generic drugs. CTC BIO possesses 5 domestic production bases, 2 research institutes, and operates local subsidiaries in the USA and Indonesia, expanding its production base by acquiring the Ansan factory from SK Chemicals in 2014. Its technological prowess is recognized through core technologies such as microbial fermentation and drug coating, alongside the development of innovative film-type and complex formulations.